You are here
Round table discussion on anaemia in cancer patients by Dr. Matti Aapro, Dr. Carla Ripamonti and Dr. Anton Snegovoy at the MASCC/ISOO Annual Meeting on 25 June 2015
Anaemia in cancer patients is an issue that needs a sophisticated approach, and there have been recent changes in the guidelines. NICE, the National Institute for Health and Care Excellence in the UK, has decided to accept the use of erythropoietins in chemotherapy-treated anaemic cancer patients.
In the USA, the costs for treating anaemia have increased with the use of erythropoiesis-stimulating agents (ESA). Dr. Ripamonti reports on an Italian study in which the costs of transfusions have decreased.
Dr. Snegovoy stresses the importance of establishing a proper diagnosis before starting anaemia treatment.
Dr. Matti Aapro, Clinique de Genolier, Genolier, Switzerland
Dr. Carla Ripamonti, Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS, Istituto Nazionale Tumori Via Venezian, Milan, Italy
Dr. Anton Snegovoy, Department of Out-patient Chemotherapy, N.N. Blokhin Russian Cancer Research Center, RAMS, Moscow, Russia